List of Excipients in Branded Drug SAFYRAL

Safyral Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Safyral is an oral contraceptive combining drospirenone, ethinyl estradiol, and levomefolate calcium. Its formulation strategy addresses two requirements in one 28-day regimen: hormonal contraception and daily folate supplementation. The strongest commercial opportunities are generic or alternative-brand development, excipient modernization, lactose-free positioning, improved stability of levomefolate, and patient-centered packaging.

Safyral was approved by the U.S. Food and Drug Administration under NDA 022532. The product contains 3 mg drospirenone, 0.03 mg ethinyl estradiol, and 0.451 mg levomefolate calcium in the hormone-containing tablets, with levomefolate calcium also supplied during the hormone-free interval.[1]

What is Safyral and how does its formulation work?

Safyral is a 28-tablet oral contraceptive product. Twenty-one tablets contain the hormonal combination, while seven tablets provide levomefolate calcium without the contraceptive hormones. This design maintains uninterrupted folate administration across the monthly cycle.

Safyral active ingredients and dosage form

Attribute	Safyral specification
Brand	Safyral
Dosage form	Oral film-coated tablet
Hormonal actives	Drospirenone and ethinyl estradiol
Folate active	Levomefolate calcium
Hormonal strength	Drospirenone 3 mg; ethinyl estradiol 0.03 mg
Folate strength	0.451 mg levomefolate calcium
Regimen	21 hormone-containing tablets followed by 7 folate-only tablets
FDA application	NDA 022532
Therapeutic category	Combined hormonal contraceptive
Primary commercial owner	Bayer HealthCare Pharmaceuticals

Drospirenone is a progestin with antimineralocorticoid and antiandrogenic properties. Ethinyl estradiol provides estrogenic activity. Levomefolate calcium is the calcium salt of the naturally occurring form of folate and is included to increase folate status in women who may become pregnant.

The product’s commercial differentiation is therefore partly pharmaceutical and partly adherence-based. A single blister pack supplies contraception and folate without requiring a separate prenatal or folic-acid product.

What excipients are used in Safyral tablets?

The Safyral label identifies conventional tablet excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, povidone, and coating components.[1] The excipient system supports direct compression or granulation, tablet disintegration, lubrication, and film coating.

Core excipient functions

Excipient category	Representative Safyral excipients	Formulation function
Diluent	Lactose monohydrate	Provides tablet bulk and compressibility
Filler and dry binder	Microcrystalline cellulose	Improves compactibility and tablet strength
Superdisintegrant	Croscarmellose sodium	Promotes rapid tablet breakup after ingestion
Binder	Povidone	Supports granule and tablet cohesion
Lubricant	Magnesium stearate	Reduces ejection force and tooling adhesion
Coating system	Hypromellose, titanium dioxide, pigments and related coating materials	Protects the tablet and supports product identification

The excipient system is typical for a low-dose immediate-release oral tablet. Its complexity arises from the very small quantities of the hormonal ingredients rather than from a modified-release mechanism.

Why the low dose changes excipient strategy

Safyral contains only 30 micrograms of ethinyl estradiol. That concentration creates a dose-uniformity challenge. Small variations in blending, segregation, granule size, or powder flow can have a material effect on content uniformity.

A robust formulation must control:

• API particle-size distribution;
• blend homogeneity;
• electrostatic segregation;
• lubricant mixing time;
• tablet weight variation;
• content uniformity;
• dissolution of both hormonal actives;
• stability of levomefolate during storage.

Microcrystalline cellulose and lactose provide a practical physical matrix for low-dose distribution. Povidone can improve cohesion, while croscarmellose sodium supports rapid disintegration. Magnesium stearate requires tight process control because excessive lubrication can reduce tablet hardness and slow dissolution.

What excipient risks affect Safyral generic development?

The main development risks are compatibility, dose uniformity, dissolution, and folate stability. A generic product does not need to copy the brand’s excipients, but it must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway.

Lactose-related risk

Lactose is commercially attractive because it is inexpensive, widely available, and compatible with many immediate-release tablet systems. Its use creates several limitations:

• lactose-intolerant patients may prefer a lactose-free product;
• reducing sugars can create compatibility concerns with amine-containing compounds;
• moisture and supplier variability can affect powder behavior;
• lactose may constrain a differentiated excipient claim.

Lactose intolerance does not automatically make a lactose-containing tablet unsuitable for every patient, but a lactose-free version could support a targeted commercial position.

Levomefolate stability

Levomefolate calcium is more formulation-sensitive than many conventional tablet fillers. Potential stressors include light, heat, humidity, oxygen exposure, and interactions with reactive excipients or process impurities.

A development program should assess:

• assay and degradation products for levomefolate;
• folate stability in both hormone-containing and folate-only tablets;
• photostability of the finished product;
• moisture uptake of the tablet and blister;
• extractables and leachables from packaging;
• stability after opening for bottle presentations.

A protective film coat and high-barrier blister can be more commercially important than a small change in tablet filler.

Magnesium stearate and dissolution

Magnesium stearate is a standard lubricant but can create dissolution variability when overmixed or used at excessive concentrations. This matters because the product contains multiple low-dose actives with different physical properties.

A generic developer may gain process robustness by using:

• lower lubricant levels;
• shorter lubrication times;
• alternative lubricants such as sodium stearyl fumarate;
• improved pre-blending controls;
• particle engineering for the active ingredients.

Any change must preserve tablet manufacturability while matching the reference product’s dissolution and exposure profile.

What formulations are protected by Safyral’s product design?

Safyral’s central formulation concept is the combination of drospirenone, ethinyl estradiol, and levomefolate calcium in a coordinated 28-day regimen. The commercial value lies in the combination and regimen rather than in a sophisticated delivery system.

Potentially protectable or differentiating features include:

1. The specific hormonal and folate combination.
2. The 21-plus-7 tablet sequence.
3. Continuous folate delivery through the hormone-free interval.
4. Tablet composition and coating.
5. Packaging designed to improve folate stability.
6. Manufacturing processes that achieve uniform distribution of microgram-level ethinyl estradiol.
7. Alternative forms of folate or folate salts.
8. Patient-specific dosage packaging.

U.S. generic competition is generally assessed through the Orange Book, applicable listed patents, regulatory exclusivity, and Paragraph IV certifications. Safyral’s formulation strategy should not be treated as equivalent to patent protection. Patent scope depends on the claims, prosecution history, expiration dates, and listing status.[2]

What is the FDA and Orange Book status of Safyral?

Safyral was approved under FDA NDA 022532. The FDA label identifies the product as a prescription oral contraceptive containing drospirenone, ethinyl estradiol, and levomefolate calcium.[1]

The Orange Book is the relevant source for identifying whether the NDA remains listed, whether patents are listed, and whether generic applicants have submitted certifications against those patents.[2] A product may be discontinued commercially without being withdrawn from the market for safety or efficacy reasons. That distinction matters for generic approval analysis, because commercial discontinuation and regulatory withdrawal are separate events.

For business planning, the relevant regulatory questions are:

• whether NDA 022532 is listed as currently marketed or discontinued;
• whether FDA has determined that the product was withdrawn for reasons of safety or efficacy;
• whether any patents remain listed;
• whether an ANDA applicant has filed Paragraph IV certifications;
• whether a therapeutically equivalent product appears in the Orange Book;
• whether reference-product sourcing is available for bioequivalence studies.

When does Safyral lose exclusivity and what generic entry risks exist?

Safyral’s market exclusivity is distinct from patent protection. FDA approval, statutory exclusivity, listed patents, and commercial availability must be analyzed separately.

Exclusivity and generic-entry framework

Issue	Commercial significance
NDA exclusivity	May restrict certain ANDA approvals for a defined period
Listed patents	Can delay approval if an ANDA includes a Paragraph IV challenge and litigation follows
Paragraph IV certification	Signals that an applicant seeks approval before listed patent expiration
Formulation differences	May require a distinct label or alternative product design
Bioequivalence	Requires demonstration against the FDA-designated reference product
Market status	Determines whether the reference product can be purchased and studied
180-day exclusivity	May give a first Paragraph IV filer temporary generic exclusivity

The largest entry risk is not necessarily patent litigation. It may be technical execution. Three-active-ingredient products require simultaneous control of hormonal assay, content uniformity, dissolution, degradation, and folate stability. A developer that uses a different excipient system must establish that the formulation does not alter exposure or product performance.

Which companies are challenging or competing with Safyral?

Competition includes branded combination contraceptives, generic drospirenone/ethinyl estradiol products, and products that provide folate separately.

Relevant competitive groups

Competitor type	Competitive effect
Generic drospirenone/ethinyl estradiol	Competes for hormonal contraception but may not include levomefolate
Generic triphasic or monophasic contraceptives	Compete on price and prescriber familiarity
Other folate-containing contraceptives	Compete directly on combined contraception and folate positioning
Separate folic-acid supplements	Reduce the need for an integrated folate product
Branded oral contraceptives	Compete through adherence, patient support, and insurance access
Long-acting reversible contraceptives	Compete with pills at the treatment-category level

A product containing the same hormones but no folate is not a complete substitute from a formulation or labeling perspective. It may, however, be a strong price competitor if prescribers view separate folate supplementation as acceptable.

How strong is the Safyral patent estate?

The strength of the estate depends on claim scope rather than the existence of a branded combination. Potential claim categories include composition claims, methods of contraception, folate supplementation, tablet sequences, and manufacturing processes.

Patent-strength considerations

• Broad composition claims may face prior-art pressure because drospirenone and ethinyl estradiol combinations were established before Safyral.
• Folate-combination claims may provide stronger differentiation if they cover a specific salt, dose, or regimen.
• Method-of-use claims can be commercially relevant but may be difficult to enforce against products with different labeling.
• Formulation claims are strongest when they capture a necessary stability or dissolution feature that competitors cannot easily design around.
• Process claims may create manufacturing barriers but often have limited blocking power if an alternative process is available.
• Patent expiration must be confirmed from the issued patent and terminal disclaimer records, not inferred from the initial filing date.

The practical estate is likely strongest around the integrated folate regimen and product-specific formulation concepts, while the basic hormonal combination is more exposed to prior art and generic substitution.

What commercial opportunities exist for Safyral excipients?

1. Lactose-free generic product

Replacing lactose with mannitol, anhydrous dibasic calcium phosphate, spray-dried cellulose, or a co-processed excipient could support a lactose-free claim. The formulation would need to maintain tablet weight, hardness, friability, disintegration, dissolution, and content uniformity.

2. High-barrier packaging

A foil-foil blister, improved desiccant system, or light-protective package could reduce levomefolate degradation. Packaging differentiation may be more defensible than a routine filler substitution if it produces measurable shelf-life benefits.

3. Improved low-dose uniformity

A co-processed excipient with controlled particle size and flow could reduce segregation of ethinyl estradiol and drospirenone. This opportunity is relevant to contract manufacturers and specialty excipient suppliers.

4. Folate-stability platform

An excipient or coating platform designed for levomefolate stabilization could be applied across oral contraceptives, prenatal vitamins, fertility products, and women’s-health combination products.

5. Simplified manufacturing

A directly compressible, low-moisture formulation could reduce granulation steps, shorten cycle time, and lower manufacturing cost. The commercial value would be highest for high-volume generic production.

6. Patient-centered presentation

Calendar blister packs, adherence labeling, multilingual instructions, and synchronized refill packaging can differentiate a lower-priced product without changing the active ingredients.

7. Alternative folate formats

A developer could assess alternative folate salts or formulations, subject to regulatory and bioequivalence requirements. The opportunity is greatest where the alternative improves stability, tablet size, or supply-chain reliability.

How does Safyral compare with separate contraception and folate products?

Safyral’s integrated formulation reduces the number of products a patient must manage. That benefit can support adherence and pharmacy convenience. Separate products may offer lower acquisition cost and greater dose flexibility, but they introduce a second prescription or supplement decision.

Criterion	Safyral-style combination	Separate contraceptive plus folate
Product count	One regimen	Two products
Folate continuity	Built into the pack	Depends on patient behavior
Dose flexibility	Limited to fixed combination	Higher
Manufacturing complexity	Higher	Lower for each individual product
Generic substitution	Requires matching multi-active product	Broad substitution options
Commercial differentiation	Combination and adherence	Price and prescribing familiarity
Packaging opportunity	High	Moderate

Key Takeaways

• Safyral combines drospirenone, ethinyl estradiol, and levomefolate calcium in a 28-day oral regimen.
• Its excipient system is based on conventional immediate-release tablet materials, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, and magnesium stearate.
• The principal technical challenge is uniform delivery of microgram-level ethinyl estradiol alongside drospirenone and levomefolate.
• Levomefolate stability creates opportunities in coating, moisture control, light protection, and high-barrier packaging.
• A lactose-free generic, a stability-enhanced product, and a manufacturing-efficient formulation are the clearest excipient-led opportunities.
• Safyral’s commercial differentiation is the combination of contraception and continuous folate supplementation, not a modified-release delivery system.
• Orange Book status, listed patents, Paragraph IV filings, and reference-product availability determine the actual generic-entry pathway.
• The strongest defensible formulation opportunities are likely to involve stability, regimen design, and manufacturing performance rather than basic tablet excipient selection.

FAQs

Is Safyral the same as Yasmin or Yaz?

No. Safyral contains drospirenone and ethinyl estradiol like Yasmin and Yaz, but it also contains levomefolate calcium and uses a specific 28-tablet folate regimen.

Can a generic Safyral use different excipients?

Yes. An ANDA applicant generally may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, labeling, and safety.

Is levomefolate calcium the same as folic acid?

No. Levomefolate calcium is a calcium salt of L-5-methyltetrahydrofolate, while folic acid is a different chemical form of vitamin B9.

Does Safyral require a special manufacturing process?

The product does not require modified-release technology, but manufacturing must control low-dose content uniformity, blend segregation, dissolution, and levomefolate stability.

What is the best commercial excipient opportunity for a Safyral-style product?

A lactose-free, stability-enhanced immediate-release tablet in high-barrier calendar packaging offers the clearest combination of patient differentiation, technical value, and commercial practicality.

References

1. U.S. Food and Drug Administration. (2010). Safyral prescribing information, NDA 022532. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2013). Abbreviated new drug application regulations and guidance for industry. FDA.

4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.